Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2014

View Archived Issues

Amniox Medical initiates clinical trial of placenta-derived diabetic foot ulcer therapy

Lion Biotechnologies enters into trial agreement with Moffitt Cancer Center

Dong Wha completes phase III study of zabofloxacin in patients with COPD

Kalydeco approved in Europe in CF for eight non-G551D gating mutations

FUJIFILM presents novel PI3K and ERK-2 inhibitors

Researchers at Xencor divulge new heterodimeric proteins

Cubist Pharmaceuticals discloses novel TRPA1 antagonists

Novel HCV NS5A inhibitors disclosed by Merck & Co.

Daiichi Sankyo recaps pipeline progress of first quarter of fiscal 2014

Janssen Pharmaceutica patents novel gamma-secretase modulators

Kyowa Hakko Kirin seeks approval in Japan for KW-3357

Esteve confirms initiation of natural history study for Sanfilippo A syndrome

OncoCyte expands clinical development of bladder cancer diagnostic

First-in-human and in vitro results presented on novel drug for pre-transplantation desensitization

AFFiRiS reports results from phase I trial of Affitope PD-01A

Chugai Pharmaceuticals reports progress during second quarter 2014

Regeneron and Sanofi to use priority review voucher for alirocumab BLA

Shionogi to sell Ezose Sciences to Sumitomo Bakelite

Cara Therapeutics initiates abuse potential trial for CR-845

FDA approves olodaterol for COPD

Cortice Biosciences to develop heart failure drug for cognitive impairment

CHBP and caspase-3 siRNAs for renoprotection against ischemia reperfusion and CsA nephrotoxicity

Solasia gains exclusive worldwide rights to darinaparsin from Ziopharm Oncology

Alexion's eculizumab obtains European orphan drug designation for myasthenia gravis

Phase III trial initiated by Isis Pharmaceuticals for ISIS-SMNRx in infants

FDA approves empagliflozin for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.